APL Drives Indonesia's Health Transformation to Expand Access to Innovative Services

PT Anugerah Pharmindo Lestari (APL), a part of Zuellig Pharma, continues to strengthen its contributions to supporting the transformation of Indonesia’s healthcare system by utilising global expertise, integrated capabilities, and strong local operations to support the Golden Indonesia 2045 vision. In a media gathering held by APL ahead of World Health Day (7 April), APL reaffirmed its commitment to expanding access to healthcare services and highlighted the importance of inclusive and sustainable health. As one of Indonesia’s leading healthcare service companies, APL’s role is increasingly relevant as the need for quality and equitable healthcare services grows across various regions of Indonesia. The expansion of coverage through the National Health Insurance (JKN) programme, which now reaches more than 98 per cent of the population, has become a crucial foundation in improving public access to healthcare services. However, Indonesia continues to face various structural challenges, including changes in disease patterns, the need for innovative therapies and more resilient healthcare supply chains, as well as ensuring that medical innovations can be accessed throughout this vast archipelago nation. “We believe that every Indonesian citizen deserves equal access to quality healthcare services,” said Christophe Piganiol, President Director of PT Anugerah Pharmindo Lestari. “In Indonesia, this means collaborative efforts to strengthen the healthcare supply chain, expand access to medical innovations, and work with partners across the healthcare ecosystem to meet local needs. We will continue to work closely with our global partners to bring relevant expertise, proven practices, and broader capabilities to Indonesia, so that we can make healthcare more accessible and improve patient care outcomes.” Beyond its core services in distribution, commercialisation, and clinical trial support, APL plays a broader role in accelerating Indonesia’s healthcare sector transformation through knowledge transfer and strategic partnerships with key stakeholders. This role positions APL not only as a healthcare company but also as a trusted long-term partner in Indonesia’s healthcare system transformation. By applying the highest standards of integrity and operational excellence, APL is also driving improvements in healthcare distribution standards in Indonesia through the use of technology in its operations. As part of an end-to-end distribution solution, APL brings global-standard technology through the National Distribution Center (NDC) equipped with advanced technology. Best-in-class cold chain handling systems, including eZCooler as a unique cold-chain packaging solution, ensure product integrity is maintained until the final delivery point. APL implements state-of-the-art digital control and visibility systems through real-time temperature monitoring at the National Distribution Center (NDC) and across its branch network, supported by integrated data systems and intelligent analytics to optimise stock and precise replenishment. The implementation of Good Distribution Practice (GDP) standards and ISO 9001:2015 certification further reinforces strict quality assurance while promoting the sustainable development of local talent competencies, ultimately enhancing the quality of Indonesia’s workforce. In response to the rising challenges of non-communicable diseases in Indonesia, APL maximises its commercialisation capabilities to bring global innovative therapies relevant to local patient needs. With deep expertise in key therapy areas such as cardiovascular, diabetes, oncology, respiratory, and immunology, APL actively serves as an educational partner for all stakeholders in the healthcare ecosystem. Through collaborations with global pharmaceutical companies, regulators, and customer partners, APL has supported more than 22,000 healthcare professionals through various educational programmes. These initiatives play a vital role in increasing understanding of non-communicable diseases and introducing the latest treatment innovations. This step also aligns with national priorities to improve care quality and patient health outcomes in Indonesia. Recognising the importance of health innovation and market access, APL continues to support the Indonesian Government and the pharmaceutical industry in addressing the need for global-standard clinical trial support. Through comprehensive distribution services and modern technology facilities, APL is capable of supporting all stages of clinical trials with reliable and regulatory-compliant processes. Thus, APL bridges the gap between global health innovations and the specific needs of the Indonesian market. The synergy of global expertise with local capabilities, along with close collaboration with the government and healthcare industry stakeholders, forms the main foundation in accelerating national health transformation. This collective effort is key to realising a more resilient and sustainable healthcare ecosystem. Sustainable health transformation requires strengthening the entire ecosystem, not only in distribution and innovation but also in talent development, health literacy, and responsible business practices. APL integrates sustainability principles into its operations, ensuring every aspect of its services delivers tangible impacts for society. By focusing on four pillars—increasing health outcomes, developing talent, respecting the environment, and upholding the highest integrity standards—APL has recorded several